Articles by Siegfried Schmitt - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Siegfried Schmitt

Siegfried Schmitt


Siegfried Schmitt, PhD, principal consultant at PAREXEL.

Articles
Data Integrity
July 2, 2014

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how to ensure data integrity.

Key Considerations for Quality-Technical Agreements
May 30, 2014

A drug sponsor?s responsibility does not end when a task is outsourced.

Quality-Technical Agreements
May 2, 2014

Siegfried Schmitt, principal consultant at PAREXEL, discusses the importance of quality-technical agreements.

The Human Factor
February 2, 2014

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how human error can be mitigated in pharmaceutical manufacturing.

The State of Drug Manufacturing in India
January 31, 2014

Some recent high-profile cases of quality issues at Indian manufacturers have given reason to examine manufacturers more closely.

Drug Manufacturing Focus: Why India?
December 2, 2013

Siegfried Schmitt, principal consultant at PAREXEL, discusses the state of drug manufacturing in India.

The Role of Analytical Science in Implementing Quality by Design
March 2, 2013

The authors present topics discussed and conclusions that resulted from the PDA QbD workshop.

The Freeze Drying Challenge
April 1, 2012

There are no two completely identical freeze dryer units in operation anywhere.

A Perspective on Computer Validation
July 2, 2007

This article provides a historical review of computer validation in the pharmaceutical industry within the last three decades, evolving from the early years' initial concept and approach to today's current practices. Also included is how the regulations and industry have progressed in addressing the topic of computer validation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here